RECQL4 affects MHC class II‐mediated signalling and favours an immune‐evasive signature that limits response to immune checkpoint inhibitor therapy in patients with malignant melanoma

Abstract Background Cancer immunotherapy has transformed metastatic cancer treatment, yet challenges persist regarding therapeutic efficacy. RECQL4, a RecQ‐like helicase, plays a central role in DNA replication and repair as part of the DNA damage response, a pathway implicated in enhancing efficacy...

Cijeli opis

Bibliografski detalji

Glavni autori:	Sara Egea‐Rodriguez, Renáta Váraljai, Thierry M. Nordmann, Restuan Lubis, Manuel Philip, Florian Rambow, Alexander Roesch, Michael Flaig, Susanne Horn, Raphael Stoll, Fang Zhao, Annette Paschen, Bert Klebl, Ian D. Hickson, Dirk Schadendorf, Matthias Mann, Iris Helfrich
Format:	Artigo
Jezik:	Inglês
Izdano:	Wiley 2025-01-01
Serija:	Clinical and Translational Medicine
Teme:	immune evasion immunotherapy melanoma MHC class II RECQL4
Online pristup:	https://doi.org/10.1002/ctm2.70094
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!